Trial reportCell reports. Medicine2021
Complete mesogastric excision for locally advanced gastric cancer: short-term outcomes of a randomized clinical trial.
Trial report in Cell reports. Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07139418 (The Clinical Significance of Examining Metastatic Lymph Nodes in Respective Gastric Mesenteries in the Gastric Cancer Patients Who Received D2 Lymphadenectomy Plus Complete Mesogastric Excision), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Clinical Significance of Examining Metastatic Lymph Nodes in Respective Gastric Mesenteries in the Gastric Cancer Patients Who Received D2 Lymphadenectomy Plus Complete Mesogastric Excision
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- Determinants of Postoperative Pulmonary Complications and Optimization Strategies for Intraoperative Respiratory Management After Laparoscopic Gastrointestinal Cancer Surgery.Annals of surgical oncology · 2026Article
- Preoperative prediction of tumor deposits in advanced gastric cancer using intratumoral and peritumoral CT radiomics: development and validation of an ensemble model.Frontiers in oncology · 2026Article
- Re-evaluation of lymph node dissection and surgical strategy for locally advanced gastric cancer in the era of neoadjuvant immunotherapy: a narrative review.Frontiers in oncology · 2026Review
- Mesenteric-guided approach to pyloric lymphadenectomy in laparoscopic radical gastrectomy.World journal of gastrointestinal surgery · 2025Article
- Correlation between laparoscopic radical resection and tumor markers in peritoneal irrigation fluid.World journal of gastrointestinal surgery · 2025Article
- DeepGuide: a novel wavelength-specific navigation system for membrane visualization in surgery.International journal of surgery (London, England) · 2025Article
- Article
- Current clinical trials on gastric cancer surgery in China.World journal of gastrointestinal oncology · 2024Review
- The short- and long-term outcomes of laparoscopic D2 lymphadenectomy plus complete mesogastrium excision for lymph node-negative gastric cancer.Surgical endoscopy · 2024Article
- Review
- Efficacy and safety of traditional Chinese medicine nursing intervention in postoperative patients after gastrectomy.Oncology letters · 2023Article
- Real-time and accurate estimation of surgical hemoglobin loss using deep learning-based medical sponges image analysis.Scientific reports · 2023Article
- Surgical and oncological outcomes of laparoscopic right hemicolectomy (D3 + CME) for colon cancer: A prospective single-center cohort study.Surgical endoscopy · 2023Article
- The short- and long-term effect of membrane anatomy-guided laparoscopic D2 lymphadenectomy plus regional complete mesogastrium excision for locally advanced gastric cancer.Surgical endoscopy · 2023Article
- Short-term outcomes of D2 lymphadenectomy plus complete mesogastric excision for gastric cancer: a propensity score matching analysis.Surgical endoscopy · 2022Observational
- Satisfactory short-term outcomes of totally laparoscopic ileostomy reversal compared to open surgery in colorectal cancer patients.Frontiers in surgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Implementation of complete mesogastric excision in gastric cancer surgery, named D2 lymphadenectomy plus complete mesogastric excision (D2+CME), has recently been proposed as an optimal procedure. However, the safety and efficacy of D2+CME remain uncertain. In this randomized controlled trial, patients receiving D2+CME exhibit less intraoperative blood loss, more lymph node harvesting, and earlier postoperative flatus than patients receiving conventional D2 radical surgery. Univariate Cox regression analysis reveals that the risk ratio for postoperative flatus in D2+CME group is 1.247 (p = 0.044). Overall postoperative complications are comparable between the two groups, but complications are significantly less severe in the D2+CME group than the D2 group (Clavien-Dindo classification grade ≥ IIIa: 4 D2+CME patients [11.8%] versus 9 D2 patients [33.3%]; p = 0.041). In conclusion, our work shows that D2+CME is associated with better short-term outcomes and surgical safety than conventional D2 dissection for patients with advanced gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.